MBAI logo

MBODY AI LTD

MBAINASDAQ
πŸ† #4385 by market capUS Equity
$487.34β–² $37.57 (+7.71%)
Simulated price
πŸ””
Track MBAI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$57M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
64
Fair
No chart data available for MBAI.

Trading Snapshot

Day Range
$483.37 – $496.99
52-Week Range
$3.88 – $27.44
Volume
$2.71B
Avg Volume
$3.41B
Shares Outstanding
7.0M
Next Earnings
Dec 9, 2026

Fundamentals Snapshot

Annual Revenue
$15M
Last Q Revenue
$4M
P/E Ratio
6.7
P/S Ratio
β€”
EPS (TTM)
$1.56
Dividend Yield
β€”

Why Investors Own MBAI

  • βœ“High-growth profile β€” revenue up +37.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 33% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MBAI logo

MBODY AI LTD

MBAI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$2Mβ–Ό βˆ’90.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$46Kβ–Ό βˆ’99.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$14Kβ–² +$122K YoY
StockOtter Β· stockotter.space

About MBODY AI LTD

Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$555.78
β–² +14.0% Upside
High Target$673.82
Low Target$500.00
Based on 28 analysts

Latest News & Updates